Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)
被引量:32
摘要
Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.
参考文献11
-
1夏永祥,张峰,李相成,孔连宝,张慧,李东华,成峰,浦立勇,张传永,钱晓峰,王平,王科,武正山,吕凌,饶建华,吴晓峰,姚爱华,邵文雨,范烨,游伟,戴新征,秦建杰,李梦芸,朱勤,王学浩.原发性肝癌10966例外科治疗分析[J].中华外科杂志,2021,59(1):6-17. 被引量:92
-
2刘昊天,钟鉴宏,FINN RS,QIN S,IKEDA M.IMbrave150研究:免疫抑制剂治疗首次取得晚期肝细胞癌一线治疗成功[J].临床肝胆病杂志,2020,36(9):2148-2148. 被引量:605
-
3Min-Ke He,Yong Le,Qi-Jiong Li,Zi-Shan Yu,Shao-Hua Li,Wei Wei,Rong-Ping Guo,Ming Shi.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma:a prospective non.randomized study[J].Chinese Journal of Cancer,2017,36(12):704-711. 被引量:119
-
4Yin Lei,Lau Wan Yee,Wei-Ping Zhou.Multiple hepatocellular carcinomas: liver resection or transcatheter arterial chemoembolization?[J].Hepatobiliary Surgery and Nutrition,2019,8(5):519-521. 被引量:4
-
5张雯雯,胡丙洋,韩骏,王宏光,王湛博,陈明易,蔡守旺,王勋,曹俊宁,史继航,张泽,田蓝天,卢实春.PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J].中华肝胆外科杂志,2020,26(12):947-948. 被引量:63
-
6Antonio Orlacchio,Fabrizio Chegai,Stefano Merolla,Simona Francioso,Costantino Del Giudice,Mario Angelico,Giuseppe Tisone,Giovanni Simonetti.Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization[J].World Journal of Hepatology,2015,7(12):1694-1700. 被引量:25
-
7Peng-Peng Li,Gang Huang,Ning-Yang Jia,Ze-Ya Pan,Hui Liu,Yun Yang,Cheng-Jian He,Wan Yee Lau,Ye-Fa Yang,Wei-Ping Zhou.Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma:a randomized comparative study[J].Hepatobiliary Surgery and Nutrition,2022,11(1):38-51. 被引量:35
-
8李阳,刘子荣,张雅敏.术中应用丁二磺酸腺苷蛋氨酸对成人左半肝切除术后残肝功能及再生的影响[J].中华普通外科杂志,2018,33(11):955-957. 被引量:11
-
9范玉梅,吴修凤.S-腺苷蛋氨酸对梗阻性黄疸患者肝蛋白质合成及肝功能的影响[J].胃肠病学和肝病学杂志,2014,23(5):563-565. 被引量:3
-
10赵露,庞勇,刘丹青.胆道金属支架植入术结合腺苷蛋氨酸治疗恶性梗阻性黄疸伴肝功能损害的疗效观察[J].中国基层医药,2013,20(18):2807-2808. 被引量:9
二级参考文献62
-
1王长友,陈永平.梗阻性黄疸肝细胞损伤机制[J].中国综合临床,2004,20(8):762-764. 被引量:16
-
2王学浩,杜竞辉,张峰,李相成,赵翰林,赵志泉,武正炎,眭元庚,徐鑫荣,张国楼,傅成章,钱建民,孙跃明,刘越健,张茂金.活体供肝原位部分肝移植一例报告[J].中华器官移植杂志,1995,16(3):133-134. 被引量:55
-
3沈镭,陆伦根.腺苷蛋氨酸在胆汁淤积性肝病治疗中的应用[J].胃肠病学,2006,11(3):190-191. 被引量:27
-
4Foucher J.,Chanteloup E.,Vergniol J.,V. De Lédinghen,王顺涛(译),陈云茹(校).瞬时弹性图诊断肝硬化:一项前瞻性研究[J].世界核心医学期刊文摘(胃肠病学分册),2006,2(8):41-42. 被引量:9
-
5王学浩,杜竞辉,赵中辛,钱建民,张峰,李相成,孔连宝,孙耀明,张浩.肝癌的现代综合治疗(附1320例报告)[J].中国实用外科杂志,1997,17(1):16-18. 被引量:25
-
6王学浩,杜竞辉,李相成,钱建民,张峰,赵中辛,张浩.原发性肝癌的现代外科治疗(附1600例报告)[J].肝胆外科杂志,1997,5(1):9-11. 被引量:6
-
7Jaeschke H.Reactive oxygen and mechanisms of inflammatory liver injury:present concepts[J].J Gastroenterol Hepatol,2011,26(Suppl 1):173-179.
-
8Copple BL,Jaeschke H,Klaassen CD.Oxidative stress and the pathogenesis of cholestasis[J].Semin Liver Dis,2010,30(2):195-204.
-
9Bruix J, Sherman M. Management of hepatocellular carcinoma: anupdate. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI:10.1002/hep.24199].
-
10Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CACancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/caac.20073].
共引文献881
-
1王凯峰,彭忠忠,张西凯,周晓,苗贤媛,王琼琼,任思家,张柏文,王艺,马越.肿瘤免疫检查点抑制剂治疗相关性肝损伤诊疗进展及存在的问题[J].肿瘤,2024,44(1):89-100.
-
2周小妹,罗波.影响三阴性乳腺癌免疫检查点抑制剂疗效的潜在生物学因素[J].肿瘤,2023,43(2):143-150. 被引量:2
-
3陈璐,宋天强,李强.晚期胆道系统肿瘤免疫治疗研究进展[J].中国实用外科杂志,2020(11):1340-1344. 被引量:4
-
4余昌中,金华,安然.肝脏胆囊双原发癌临床病理分析及文献复习[J].诊断病理学杂志,2022,29(9):830-833.
-
5王楠,薛国亮,徐静雯,危志刚,叶欣.微波消融在载药微球经肝动脉化疗栓塞术联合靶向和免疫治疗进展期原发性肝癌中的应用[J].中华肿瘤防治杂志,2023,30(14):865-870. 被引量:8
-
6石明,何敏柯,陈敏山.肝动脉灌注化疗的现状与前景[J].外科理论与实践,2020,25(1):10-14. 被引量:10
-
7杨荣,范建高.非酒精性脂肪性肝病相关肝细胞肝癌的研究进展[J].临床内科杂志,2022,39(12):793-796. 被引量:8
-
8Andreas Schicho,Claus Hellerbrand,Kristina Krüger,Lukas P.Beyer,Walter Wohlgemuth,Christoph Niessen,Ernst Hohenstein,Christian Stroszczynski,Philippe L.Pereira,Philipp Wiggermann.Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels[J].Journal of Clinical and Translational Hepatology,2016,4(4):288-292. 被引量:14
-
9Masatoshi Kudo.A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma[J].Hepatobiliary Surgery and Nutrition,2020,9(4):530-533.
-
10Di-Yang Xie,Zheng-Gang Ren,Jian Zhou,Jia Fan,Qiang Gao.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J].Hepatobiliary Surgery and Nutrition,2020,9(4):452-463. 被引量:97
同被引文献143
-
1无.原发性肝癌诊疗规范(2019年版)[J].肝癌电子杂志,2020(1):5-23. 被引量:42
-
2Shima Ghavimi,Tehila Apfel,Hamed Azimi,Alana Persaud,Nikolaos T.Pyrsopoulos.Management and Treatment of Hepatocellular Carcinoma with Immunotherapy:A Review of Current and Future Options[J].Journal of Clinical and Translational Hepatology,2020,8(2):168-176. 被引量:20
-
3Amir A. Rahnemai-Azar,Jordan M. Cloyd,Sharon M. Weber,Mary Dillhoff,Carl Schmidt,Emily R. Winslow,Timothy M. Pawlik.Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency[J].Journal of Clinical and Translational Hepatology,2018,6(1):97-104. 被引量:18
-
4DaeHee Kim,Joshua Cornman-Homonoff,David C.Madoff.Preparing for Iiver surgery with "Alphabet Soup": PVE, ALPPS, TAE-PVE, LVD and RL[J].Hepatobiliary Surgery and Nutrition,2020,9(2):136-151. 被引量:14
-
5Tianfu Wen,Chen Jin,Antonio Facciorusso,Matteo Donadon,Ho-Seong Han,Yilei Mao,Chaoliu Dai,Shuqun Cheng,Bixiang Zhang,Baogang Peng,Shunda Du,Changjun Jia,Feng Xu,Jie Shi,Juxian Sun,Peng Zhu,Satoshi Nara,JMichael Millis,Qiu Li,Weixia Chen,Wusheng Lu,Hong Tang,Lvnan Yan,Yong Zeng,Bo Li,Jiayin Yang,Wentao Wang,Hong Wu,Mingqing Xu,Zheyu Chen,Changli Lu,Chuan Li,Wei Peng,Xiaoyun Zhang.Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus[J].Hepatobiliary Surgery and Nutrition,2018,7(5):353-371. 被引量:45
-
6王猛,周志刚,路太英,杜可朴,李帅,高飞,李亚丹,高梦宇.肝动脉灌注化疗联合靶向免疫序贯^(125)I粒子植入治疗肝细胞癌伴门静脉癌栓的疗效分析[J].中华医学杂志,2024,104(4):290-296. 被引量:1
-
7梅铭惠,陈谦,杨景红,徐静,邱维加,曾思恩,唐建华.肝癌合并门静脉癌栓的临床病理分级及意义[J].中华肝胆外科杂志,2006,12(6):374-377. 被引量:16
-
8冯建东.多烯磷脂酰胆碱佐治原发性肝癌临床分析[J].现代中西医结合杂志,2014,23(6):616-617. 被引量:7
-
9Wu Junyi Sun Hongcheng Han Zhongbo Peng Zhihai.A single center experience: post-transplantation adjuvant chemotherapy impacts the prognosis of hepatocellular carcinoma patients[J].Chinese Medical Journal,2014(3):430-434. 被引量:9
-
10无,滕皋军,安天志,高嵩,靳勇,刘嵘,潘杰,张齐,李家平(校正).中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].介入放射学杂志,2018,27(12):1117-1126. 被引量:76
引证文献32
-
1Lei Zhao,Haitao Zhao,Huichuan Sun.It’s time to propose a uniform criteria for determining “clinical complete response” in hepatocellular carcinoma[J].Hepatobiliary Surgery and Nutrition,2022,11(4):620-622. 被引量:1
-
2潘扬勋,陈敏山.血管介入治疗在中晚期肝癌综合治疗中的角色[J].科技导报,2023,41(18):52-57.
-
3巩辰宇,谭凯,苑浩然,白亮亮,窦港,赵瑶瑶,贺小军,杜锡林.初治不可切除肝细胞癌经仑伐替尼、FOLFOX4-HAIC、ICIs三联方案转化切除8例[J].空军军医大学学报,2024,45(1):115-120. 被引量:2
-
4李林林(综述),郝丹丹,王玉敏(审校).非编码RNA调控铁死亡在肝细胞癌中作用的研究进展[J].河北医科大学学报,2024,45(2):191-195.
-
5王鹏程,廖晖,徐小平.基于FOLFOX方案的肝动脉灌注化疗在肝癌围手术期的应用进展[J].肝胆胰外科杂志,2024,36(2):110-115. 被引量:2
-
6瞿伟峰,史颖弘,樊嘉.美国国立综合癌症网络临床实践指南:肝细胞癌(2023.V2)更新解读[J].临床外科杂志,2024,32(1):6-9. 被引量:3
-
7中国医师协会肝癌专业委员会,沈锋,程树群,孙居仙,夏勇.肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J].中华消化外科杂志,2024,23(2):153-164. 被引量:6
-
8宋燕京,乔江春,宋京海.中晚期肝癌TACE联合免疫靶向转化治疗后右半肝切除术一例[J].中华肝脏外科手术学电子杂志,2024,13(2):227-230. 被引量:1
-
9熊坚威,李强,唐涛,张立鑫,英保,赵开烽,熊永福,李敬东,武国.经肝动脉化疗栓塞联合酪氨酸激酶抑制剂及程序性死亡受体-1抗体治疗中晚期不可切除肝细胞癌的临床疗效和安全性分析[J].临床外科杂志,2024,32(2):176-181.
-
10李新,李智宇.残肝体积不足的肝恶性肿瘤患者转化治疗的研究进展[J].肝癌电子杂志,2024,11(1):16-20.
二级引证文献20
-
1吕鲁闽,卓忠贵.腹腔镜结直肠癌根治术联合微波消融术与联合腹腔镜肝切除术的疗效比较[J].贵州医科大学学报,2024,49(2):280-286.
-
2宋瑞鹏,袁玉斌,王永帅,孟凡征,张珅瑜,刘连新,王继洲.腹腔镜与开放手术治疗肝细胞癌伴有微血管侵犯病人预后对比研究[J].中国实用外科杂志,2024,44(5):571-576.
-
3赵磊,钟敬涛,孙惠川.肝细胞癌的转化治疗中几个重要却尚无答案的问题[J].外科理论与实践,2024,29(2):106-113.
-
4伍路,张向化,夏勇,沈锋.微血管侵犯预测在肝胆肿瘤治疗决策中的应用价值[J].中华消化外科杂志,2024,23(7):912-918.
-
5姜树森,谭李军,李顺刚,姚红兵.动脉灌注化疗联合全身性药物治疗中晚期肝细胞癌的应用与思考[J].中国普通外科杂志,2024,33(7):1162-1171.
-
6聂宏,仲斌演,沈健,朱晓黎.酪氨酸激酶抑制剂联合免疫检查点抑制剂在中晚期肝细胞癌二线治疗中的效果及安全性分析[J].临床肝胆病杂志,2024,40(8):1620-1626. 被引量:1
-
7卢实春.晚期肝细胞癌转化治疗的挑战与思考[J].临床肝胆病杂志,2024,40(9):1738-1740. 被引量:1
-
8季军,黄纪伟.原发性肝细胞癌转化治疗研究进展[J].肝胆外科杂志,2024,32(4):315-317.
-
9王志丹,张微.青藤碱调控COX-2/VEGF通路抑制肝癌HepG2细胞增殖和侵袭[J].解剖科学进展,2024,30(4):429-431.
-
10王恺悌,巴登才仁·安蕊,丛赟,张瑞青,邵英梅,吐尔干艾力·阿吉.肝细胞癌微血管侵犯术后早期复发的研究进展[J].中国普外基础与临床杂志,2024,31(11):1399-1405. 被引量:1
-
1Hai-Tao Zhao,Jian-Qiang Cai.Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma[J].World Journal of Gastroenterology,2021,27(47):8069-8080. 被引量:11
-
2Rishi Philip Mathew,Merin Jose,Vinayak Jayaram,Paul Joy,Danny George,Maria Joseph,TeenaSleeba,Ajith Toms.Current status quo on COVID-19 including chest imaging[J].World Journal of Radiology,2020,12(12):272-288. 被引量:1
-
3Information for Authors[J].Chinese Optics Letters,2022,20(2).
-
4Xiaobo Yang,Haifeng Xu,Bangyou Zuo,Xu Yang,Jin Bian,Junyu Long,Dongxu Wang,Junwei Zhang,Cong Ning,Yanyu Wang,Ziyu Xun,Yunchao Wang,Xin Lu,Yilei Mao,Xinting Sang,Haitao Zhao.Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J].Hepatobiliary Surgery and Nutrition,2021,10(4):434-442. 被引量:21
-
5Cong Ning,Xinmu Zhang,Xiaobo Yang,Xinting Sang,Haitao Zhao,Hanping Wang.Conversion therapy of stage IVb unresectable gallbladder carcinoma[J].Hepatobiliary Surgery and Nutrition,2022,11(2):335-337. 被引量:1
-
6Jin-Fei Ma,Lu-Yan Chen,Shuang-Ling Wu,Ying-Ying Xu,Fan Yao,Feng Jin,Pei-Fen Fu,Bo Chen.Clinical practice guidelines for ultrasound-guided breast lesions and lymph nodes biopsy: Chinese society of breast surgery (CSBrS) practice guidelines 2021[J].Chinese Medical Journal,2021(12):1393-1395. 被引量:6
-
7Daniel H.Ahn,Tanios Bekaii-Saab.Editorial comment on:“Systemic treatment of hepatocellular carcinoma:an EASL position paper”[J].Hepatobiliary Surgery and Nutrition,2022,11(1):112-114.
-
8Xi-yin ZHANG,Yi LIU,Wei-jun ZHANG,Xin-yang SONG,Yu-yang YANG.Acu-moxi Around the World Analysis and reflection of characteristics of evidence review by CMS on acupuncture treatment for chronic low back pain[J].World Journal of Acupuncture-Moxibustion,2021,31(1):59-64. 被引量:6
-
9Leana Frankul,Catherine Frenette.Hepatocellular Carcinoma:Downstaging to Liver Transplantation as Curative Therapy[J].Journal of Clinical and Translational Hepatology,2021,9(2):220-226. 被引量:3
-
10Lei Xu,Lin Chen,Wei Zhang.Neoadjuvant treatment strategies for hepatocellular carcinoma[J].World Journal of Gastrointestinal Surgery,2021,13(12):1550-1566. 被引量:4